Experimental and Molecular Medicine (2019-08-01)

Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer

  • Young-Woo Kim,
  • Young-Ho Kim,
  • Yura Song,
  • Han-Seong Kim,
  • Hye Won Sim,
  • Shiv Poojan,
  • Bang Wool Eom,
  • Myeong-Cherl Kook,
  • Jungnam Joo,
  • Kyeong-Man Hong

Journal volume & issue
Vol. 51, no. 8
pp. 1 – 10


Read online

Cancer: Tell-tale signs of recurrence Fragments of tumor DNA, or circulating tumor DNA (ctDNA), in blood can help predict stomach cancer recurrence within 12 months of surgery. Kyeong-Man Hong at the National Cancer Center, in Goyang-si, South Korea, and colleagues, carried out whole genome sequencing of stomach tumor samples from 25 patients to identify personalized cancer-specific rearranged DNA sequences. When they used this information to monitor ctDNA in blood samples obtained after surgical removal of the tumor, they found a significant correlation between the presence of ctDNA and cancer recurrence. In most cases, ctDNA was detected around four months prior to clinical recurrence, highlighting the potential usefulness of ctDNA monitoring. The lack of correlation between ctDNA levels and tumor size suggests that further research into the factors determining ctDNA levels is needed.